U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07087158) titled 'A Phase II Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma' on July 18.
Brief Summary: This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.
Study Start Date: Aug. 10
Study Type: INTERVENTIONAL
Condition:
Renal Cell Carcinoma (RCC)
Intervention:
DRUG: IBR854
Every 21 days is one cycle, and IBR854 will be dosed in a route of intravenous infusion on day 1 and day 8 of each cycle with a fixed dose of 9.0x10^9 cells.
DRUG: Pazopanib
P...